Written question asked by Steve Darling (Liberal Democrat) on Friday, 10 July 2026, in the House of Commons. It was due for an answer on Tuesday, 14 July 2026. It was answered by Preet Kaur Gill (Labour) on Friday, 17 July 2026 on behalf of the Department of Health and Social Care.
Breast Cancer: Drugs
- Question
-
To ask the Secretary of State for Health and Social Care, what steps his department has taken to make the drug Enhertu available for people with secondary breast cancer in England, following the increase in NICE’s cost effectiveness thresholds in April 2026.
- Answer
-
Following the increase in the National Institute for Health and Care Excellence’s (NICE) cost-effectiveness thresholds in April 2026, NICE, NHS England, and the manufacturers have resumed discussions to explore whether a commercial offer can be agreed that would make Enhertu cost-effective for HER2-low metastatic or unresectable breast cancer.
NICE previously published guidance in July 2024 and did not recommend Enhertu for this indication because the cost-effectiveness estimates were above the acceptable range for National Health Service resources.
Those discussions are ongoing. NICE and NHS England remain committed to securing access to effective treatments where they represent value for NHS patients.
Secondary information
- Type
- Written question
- Reference
- 17825
- Session
- 2026-27
- Related items
- Subjects
- Cost effectiveness Breast cancer Drugs Medical treatments Trastuzumab deruxtecan
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-09-21 15:54:01 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/17825
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/17825
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/17825